Results 141 to 150 of about 14,002 (252)

Association between adherence to the Dietary Approaches to Stop Hypertension diet and depression and anxiety severity in the Mashhad Stroke and Heart Atherosclerotic Disorder study population. [PDF]

Public Health Nutr
Soltani S, Rahimi HR, Seifi N, Omouri-Kharashtomi M, Norouzkhani N, Ahsan M, Mohtarami M, Mohammadian Sadabad F, Sarvari N, Ferns GA, Ghayour-Mobarhan M.   +10 more
europepmc   +1 more source

Weight Regain After Incretin Treatment: The Lean Mass Deficit Hypothesis and a Role for Testosterone Combination Therapy in Men

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1RA and triple (GIP)/GLP‐1RA/glucagon agonists achieve placebo‐subtracted weight loss of 15% to 22%. Their long‐term value depends on how well the weight loss is maintained and on the composition of weight loss, not only
Michael Zitzmann, Zsolt Bosnyak, Richard Jones, Monica Caliber   +3 more
wiley   +1 more source

Adherence to the combined Mediterranean-dietary approaches to stop hypertension diet is shaped by neighborhood socio-economics and food environments. [PDF]

Health Place
Heneghan JL, Velmurugan K, Weatherwax C, Bartsch SM, Martin CK, Powell-Wiley TM, Cohen N, McCrory MA, Horn A, Chin KL, Shah TD, Fraser KT, Petruccelli SA, Dibbs AM, Scannell SA, de la Haye K, Lee BY.   +16 more
europepmc   +1 more source

Glycaemic Management and Pregnancy Outcomes in HNF1A‐MODY

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Introduction Birthweight of HNF1A‐affected offspring is largely similar to the background population with rarely reported cases of large for gestational age (LGA) and neonatal hypoglycaemia (NH). Conventional clinical management of pre‐gestational diabetes appears to be sufficient in managing HNF1A‐affected women in pregnancy.
M. T. Crowley, P. McCluskey, N. Ng, B. Sanchez‐Lechuga, A. Fleming, M. Hatunic, B. Kinsley, S. Bacon, K. Colclough, M. Kennelly, M. M. Byrne   +10 more
wiley   +1 more source

Effect of dietary approaches to stop hypertension diet on insulin resistance and lipid accumulation product in subjects with metabolic syndrome. [PDF]

Sci Rep
Sangouni AA, Hosseinzadeh M, Parastouei K.   +2 more
europepmc   +1 more source

Digital Food Purchase Signatures and Their Response to GLP‐1‐Based Treatment in People With Obesity

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To characterise digital food purchase signatures in adults with obesity (OB) versus normal‐weight (NW) controls and explore changes from pre‐treatment to early (5‐month) and later (10‐month) phases of glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) therapy, including high and low weight‐loss responders.
Freya Orban, Laura Fernandez Cerro, Melanie Stoll, Maurice Rupp, David Herzig, Lia Bally   +5 more
wiley   +1 more source

Association between genetic risk and adherence to the Dietary Approaches to Stop Hypertension diet for developing venous thromboembolism. [PDF]

Res Pract Thromb Haemost
Li S, Jiang M, Guan Y, Cao X, Shao Z, Deng J, Hao X.   +6 more
europepmc   +1 more source

Longitudinal Taxonomic and Predicted Functional Gut Microbiome Responses to Tirzepatide and Semaglutide: An Exploratory Secondary Analysis of the OMDOT‐1 Randomized Controlled Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Glucagon‐like peptide‐1‐based therapies improve metabolic outcomes, but longitudinal gut microbiome dynamics remain poorly characterized. We compared taxonomic and predicted functional microbiome responses to tirzepatide and semaglutide in Type 2 diabetes.
Tomoaki Morioka, Daichi Miyaoka, Susumu Nakatani, Yoshinori Kakutani, Shoko Miyamoto, Yu Nagakura, Miho Uematsu, Takehiro Hirano, Hidekatsu Yae, Mako Yamamoto, Noriaki Sato, Kosuke Fujimoto, Masanori Emoto, Seiya Imoto, Satoshi Uematsu   +14 more
wiley   +1 more source

Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Semaglutide, a glucagon‐like peptide‐1 (GLP‐1) receptor agonist, is approved for cardiovascular risk reduction in individuals with overweight or obesity and cardiovascular disease. Whether tirzepatide, a dual GLP‐1 and glucose‐dependent insulinotropic polypeptide receptor agonist, has similar cardiovascular benefits remains unknown.
Gwen Aubrac, Rafeya V. Raquib, Minh T. Le, Michael Webster‐Clark, Robert W. Platt, Andrew C. Stokes   +5 more
wiley   +1 more source

Periodontitis and atherosclerotic cardiovascular disease: A critical appraisal

Periodontology 2000, EarlyView., 2023
Abstract In spite of intensive research efforts driving spectacular advances in terms of prevention and treatments, cardiovascular diseases (CVDs) remain a leading health burden, accounting for 32% of all deaths (World Health Organization. “Cardiovascular Diseases (CVDs).” WHO, February 1, 2017, https://www.who.int/news‐room/fact‐sheets/detail ...
Maria Clotilde Carra, Hélène Rangé, Giuseppina Caligiuri, Philippe Bouchard   +3 more
wiley   +1 more source